Troutman Pepper Represents Cognition Therapeutics in Initial Public Offering

NEW YORK – Troutman Pepper client Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company, recently launched an initial public offering with the expected gross proceeds of approximately $45.2 million. Read a company press release announcing the pricing of its upsized IPO.

Cognition Therapeutics is engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company aims to develop disease-modifying treatments for patients with these disorders by targeting the σ-2 (sigma-2) receptor, a key regulator of cellular damage cellular damage response.

The Troutman Pepper team advising Cognition Therapeutics was led by Rachael M. Bushey, Joseph Walsh, and Raymond A. Miller, and included Pierre Queiroz de Oliveira, Alexander Yarbrough, Michael Brito-Stamm, Immanuel Kim, Benjamin Stowers, Allison Nicklin, Judith O’Grady, Noreen Hibbard Onimus, David Kaplan, Sheri Adler, and Kahn Wiedis.

Troutman Pepper regularly counsels pharmaceutical, biotech, medical device, diagnostics, and other life sciences clients on all types of corporate matters, including in major mergers and acquisitions. The multidisciplinary team applies deep industry know-how and market insight to provide holistic guidance throughout clients’ business cycles.

About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm’s litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients’ most pressing business challenges, with depth across industry sectors, including construction, energy, finance, health sciences, insurance, private equity, real estate, and technology, among others. Learn more at troutman.com.